ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRash is a frequently observed adverse effect of gemcitabine (GEM) plus nanoparticle albumin-bound paclitaxel (nab-PTX) therapy for pancreatic cancer. However, the clinical characteristics of this reaction remain poorly understood. In this study, we aimed to identify factors associated with the development of rash during GEM plus nab-PTX therapy for pancreatic cancer in a real-world setting.
methodsPatients with pancreatic cancer receiving GEM plus nab-PTX (n = 313) were retrospectively evaluated. The primary endpoint was to identify factors associated with all-grade rash during the first cycle. The secondary endpoint was the change in eosinophil levels from baseline to the nearest assessment time point after rash development in patients who developed symptoms.
resultsThe incidence of all-grade rash was 20.4%, with grades 1 and 2 accounting for 18.5% and 1.9%, respectively. Multivariable logistic regression analysis identified baseline renal impairment as an independent risk factor and the regular co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) as a protective factor for rash development (adjusted odds ratio [95% confidence interval]: 2.01 [1.03-3.91], P = 0.04 for renal impairment; and 0.44 [0.20-0.91], P = 0.03 for NSAID co-administration). Eosinophilia at the nearest time point after symptom onset occurred in 12.5% of patients with rash, with eosinophil levels significantly elevated from baseline, suggesting partial involvement of an immune-mediated mechanism.
conclusionOur study identified baseline renal impairment as a risk factor and regular NSAID co-administration as a protective factor against rash development during real-world GEM plus nab-PTX therapy for pancreatic cancer.
Indexed as
Identifiers
42671618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.